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Introduction
Nowadays, colorectal cancer is known as one of the
most common types of gastrointestinal cancer with high
mortality rate worldwide. Recently, the association
between the development of the cancer and viral infec-
tions has been widely investigated with controversial
results. The current study was conducted to detect the
association of CMV and EBV prevalence with colorectal
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cancer in the respective patients, and compare the pre-
valence rates of the two conditions between patients
and healthy individuals.
Methods
A total of 80 tissue blocks (58 from colon and 22 from
rectum) of the patients with colorectal cancer and 80
samples (58 from colon and 22 from rectum) from nor-
mal counterparts were obtained. The block samples
were deparaffinized and the viral DNA was extracted
using a commercially available kit. CMV and EBV
nucleic acids were detected by nested-PCR method
using specific outer and inner primer sets. The results
were statistically compared between different groups by
SPSS for Windows (version 16, SPSS Inc., Chicago, IL,
USA).
Results
CMV DNA was detected in 7/80 (8.7%) of patients; all
in colon cancer group. Furthermore, EBV DNA was
detected in 70/80 (87.5%) of patients, consisting of
50/58 (5%) with colon cancer and 20/22 (90.9%) with
rectum cancer. Among the healthy individuals, the
CMV and EBV nucleic acids were detected in 4/80 (5%)
and 65/80 (81.25%), respectively. The statistical analysis
showed no significant difference between the prevalence
rates of CMV and EBV infections in cancer patients and
the healthy group (p > 0.05).
Conclusion
Taken together, our findings revealed that the prevalence
rates of both CMV and EBV infections were higher in
colorectal cancer group than those in the normal one,
though the differences were not statistically significant
among them. Given the importance of the viral infections
in the incidence of colorectal cancers, to reduce the
infection complications in the cancer patients, a screen-
ing program is highly suggested.
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Table 1 Analysis of EBV infection prevalence among
different studied groups.
Variable Frequency p-value
Health condition Healthy 65/80 (81.25%)
Cancer patients 70/80 (87.5%) P=0.384
Sex Male 87/100 (87%)
Female 48/60 (80%) P=0.265
Location Urban 80/93 (86%)
Rural 55/67 (82.1%) P-0.516
Table 2 Analysis of CMV infection prevalence among
different studied groups.
Variable Frequency p-value
Health condition Healthy 4/80 (5%)
Cancer patients 7/80 (8.7%) P=0.534
Sex Male 4/100 (4%)
Female 7/60 (11.6%) P=0.103
Location Urban 5/93 (5.4%)
Rural 6/67 (8.9%) P=0.528
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